Our “people first” culture ensures we are responsive and attentive to needs – yours and ours. Click on our team to read more.

A time proven project leader and line manager with 30 years’ industry experience in UK and Sweden. During his career he has worked across a broad range of disciplines, including clinical, laboratory and sales and marketing. This spans numerous therapeutic areas, including respiratory, oncology, CNS, infection and ophthalmology. Since co-founding Aptus Clinical, Jonathan has helped build the business and grow the client portfolio.

Patti brings more than 24 years of finance experience, 20 of those in the clinical research industry. She has a diverse background in financial leadership and a passion for team engagement and talent management. Patti started her professional career as a tax consultant at Deloitte & Touche LLP, then moved into the healthcare field with a senior finance role at NES, an emergency room staffing and management company. She got her start in the clinical research industry in 2000 at PPD. During her tenure there she held a variety of roles, including tax, operations finance leadership and more recently ownership of the government business unit. While at PPD Patti played an important part in the significant growth of the company, both related to adding service offering and expanding internationally. She led the globalization of finances for the clinical development business unit and partnered with business unit leadership to optimize revenue and profitability. When Patti isn’t crunching numbers at Catalyst, she enjoys being outside with family and friends – first choice is beach and traveling, followed closely by anything active – volleyball, walking, pool and playing with her two yellow lab mutts. Go fetch.

Nik started his career as a biostatistician with Smithkline Beecham (now GSK) where he worked for ~7 years before moving to join PPD.  While at PPD, Nik spent four years in Project Management, leading the Hematology and Oncology portfolio for two. In 2010 he took on the global leadership role for Biostatistics and Programming (and ironically was a client/partner of Triangle Biostatistics). In 2016 Nik became Senior VP Site and Patient Access, leading the newly formed function accountable globally for selecting and activating sites and accelerating clinical trial access for patients across all therapeutic areas.  In January 2020, Nik launched a new business unit focused on the design and implementation of digitally enabled and decentralized trials.  The timing coincided with the Covid-19 pandemic introducing extreme demand for the solutions from this new “startup” Nik was leading and he oversaw the significant growth of that group and the establishment of those solutions.  Nik joined Catalyst in April 2022 as Chief Operating Officer.

Marshall brings almost 30 years of experience in large multi-national companies and small operations to Catalyst.  He has extensive global experience including an expatriate assignment to the UK, as well as mergers and acquisitions experience across multiple countries. The majority of his career has been in and around the pharmaceutical/drug development industries. Marshall’s early career was in research with Indianapolis-based Eli Lilly and Company. His focus was on structure-based drug design and his scientific work resulted in six US patents. He transitioned into the decision sciences group at Lilly where the focus was on decision and risk analysis. He ultimately transitioned into Human Resources where he has remained. His career included roles at Wilmington-based aaiPharma and GE Nuclear before he ended up at PPD. Skelton has a BS in Chemistry from Furman University, an MS in Chemistry from the University of Georgia, and an MBA from the University of Indianapolis.

Marshall and his wife Vivian have three children and are dedicated to causes in and around Wilmington. He is actively involved in Port City Community Church and was on the board for many years, including 2 years as chairman of the board.   He served on the foundation board for Lower Cape Fear Hospice; including a stint as chairman.  He is currently on the board for the Friends of the New Hanover County Arboretum where he serves as treasurer. Other past roles include the UNCW Cameron School of Business International Advisory Board, the Chamber of Commerce Foundation, and a participant in Leadership Wilmington 2007. Marshall is also an NC State Extension Master Gardner and is a PADI Rescue Scuba Diver.      

Keya is responsible for the quality and delivery of the clinical trial portfolio within the Catalyst CRO services business unit. Throughout her 22-year career in clinical research with both biopharma and clinical service providers, Keya has provided oversight of multidisciplinary teams in project management, clinical monitoring and site support services. She also served as an executive in both operational and commercial roles and has been involved in several complex, global trials in various therapeutic areas and phases with a concentration on hematology and oncology programs. Keya prides herself on building and managing high-functioning teams that deliver excellence while ultimately bringing meaningful therapies to patients in need. Previously, she served as vice president of clinical operations at Clinipace, senior vice president of clinical services at WIRB-Copernicus Group, senior vice president at ePharmaSolutions  and executive vice president of clinical development at Omnicare Clinical Research. When she isn’t supporting customers fighting cancer, Keya enjoys spending time with her husband and two teenage sons and taking long rides with her husband on their Harley motorcycles. Vroom, vroom.

Andrew has focused exclusively in oncology for over 20 years and serves as the VP of Oncology Drug Development for Catalyst.  He is a cell & molecular biologist with a Ph.D. from Columbia University and a B.S. from MIT, and leads Catalyst’s full-service oncology solution, supporting study optimization, delivery oversight, training and new initiatives across the commercial and operational teams to keep Catalyst at the forefront of industry trends and cutting-edge oncology therapies.  Bringing a broad base of oncology experience to Catalyst, Andrew began his professional career at a niche oncology CRO, Prologue Research, which was founded out of what became the James Cancer Center at The Ohio State University and acquired in 2010 by Novella Clinical.  At Novella, Andrew led the growth of the organization’s oncology division into a market-leading oncology specialty CRO. After the acquisition of Novella by Quintiles, Andrew spent nearly seven years working within the standalone CRO which was subsequently rebranded to IQVIA Biotech in 2019.  Andrew enjoys a wide range of extracurricular activities from coaching a local travel baseball team (he played in college), cheering his son on who is a goalie for the AAA Blue Jackets (Andrew can’t skate), sneaking away for the occasional video game (he’s terrible at Fortnite), and being impressed by his daughter’s musical, dance and engineering talents (he can neither confirm nor deny the existence of some video of his a cappella group from college).  Andrew lives in Columbus, Ohio with his amazing wife Brooke and their 2 kids, where they enjoy family time, travel, and any game they can get their hands on.